Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors - Trial NCT00198172
Access comprehensive clinical trial information for NCT00198172 through Pure Global AI's free database. This Phase 2 trial is sponsored by Indiana University School of Medicine and is currently Terminated. The study focuses on Germ Cell Tumor. Target enrollment is 37 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Indiana University School of Medicine
Indiana University
Timeline & Enrollment
Phase 2
Oct 01, 2000
Mar 01, 2007
Primary Outcome
To determine the feasibility and toxicity of combining epirubicin to fixed dose cisplatin
Summary
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with
 refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage
 chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study
 E39897.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00198172
Non-Device Trial